- Corporate Officers - S
- Sherwin Stephen A
Insider Trading History of Sherwin Stephen A
The following table details the insider trading activities
(stock purchases, stock sales, and stock option exercises) of Sherwin Stephen A since 2005.
This trader's CIK number is 1079462.
At the time of last reporting, Sherwin Stephen A was the Director of Neurocrine Biosciences Inc. (stock ticker symbol NBIX).
Also see all insider trading activities at Neurocrine Biosciences Inc.
Note that in the past
SHERWIN STEPHEN A also reported insider trading activities as an insider of the following companies:
Yearly summary of insider trading at Fresh Tracks Therapeutics, Inc. (VICL) by Sherwin Stephen A
| | Insider Buying | Insider Sales | Option Exercises |
|---|
| Year | Symbol | Shares | Value | Shares | Value | Shares | Value |
|---|
| 2013 | VICL | 7,003 | $70 | 0 | $0 | 0 | $0 |
Yearly summary of insider trading at Cell Genesys Inc (CEGE) by Sherwin Stephen A
| | Insider Buying | Insider Sales | Option Exercises |
|---|
| Year | Symbol | Shares | Value | Shares | Value | Shares | Value |
|---|
| 2005 | CEGE | 2,500 | $12,387 | 0 | $0 | 0 | $0 |
Yearly summary of insider trading at Biogen Inc. (BIIB) by Sherwin Stephen A
| | Insider Buying | Insider Sales | Option Exercises |
|---|
| Year | Symbol | Shares | Value | Shares | Value | Shares | Value |
|---|
| 2025 | BIIB | 0 | $0 | 8,760 | $1,314,140 | 0 | $0 |
| 2020 | BIIB | 0 | $0 | 2,434 | $718,645 | 12,278 | $717,771 |
| 2015 | BIIB | 0 | $0 | 6,000 | $2,458,020 | 6,000 | $358,920 |
| 2014 | BIIB | 0 | $0 | 5,500 | $1,535,429 | 5,500 | $329,010 |
| 2013 | BIIB | 0 | $0 | 14,325 | $3,253,852 | 12,825 | $767,191 |
| 2012 | BIIB | 0 | $0 | 4,500 | $607,925 | 0 | $0 |
| 2011 | BIIB | 0 | $0 | 2,500 | $277,200 | 0 | $0 |
Yearly summary of insider trading at Neurocrine Biosciences Inc (NBIX) by Sherwin Stephen A
| | Insider Buying | Insider Sales | Option Exercises |
|---|
| Year | Symbol | Shares | Value | Shares | Value | Shares | Value |
|---|
| 2025 | NBIX | 0 | $0 | 13,831 | $1,613,925 | 2,869 | $0 |
| 2024 | NBIX | 0 | $0 | 40,000 | $5,338,600 | 44,199 | $1,813,000 |
| 2023 | NBIX | 0 | $0 | 60,000 | $7,131,480 | 60,000 | $770,700 |
| 2022 | NBIX | 0 | $0 | 15,000 | $1,116,375 | 15,000 | $99,900 |
| 2020 | NBIX | 0 | $0 | 17,687 | $1,757,963 | 0 | $0 |
| 2018 | NBIX | 0 | $0 | 10,000 | $984,419 | 15,000 | $105,750 |
| 2017 | NBIX | 0 | $0 | 0 | $0 | 15,000 | $51,000 |
| 2016 | NBIX | 0 | $0 | 0 | $0 | 30,000 | $117,450 |
| 2014 | NBIX | 0 | $0 | 0 | $0 | 12,000 | $148,440 |
| 2013 | NBIX | 0 | $0 | 0 | $0 | 12,000 | $127,200 |
Yearly summary of insider trading at Verastem, Inc. (VSTM) by Sherwin Stephen A
| | Insider Buying | Insider Sales | Option Exercises |
|---|
| Year | Symbol | Shares | Value | Shares | Value | Shares | Value |
|---|
| 2014 | VSTM | 2,500 | $21,395 | 0 | $0 | 0 | $0 |
Insider trading activities at 5 companies by Sherwin Stephen A:
1. Fresh Tracks Therapeutics, Inc. (VICL)
2. Cell Genesys Inc (CEGE)
3. Biogen Inc. (BIIB)
4. Neurocrine Biosciences Inc (NBIX)
5. Verastem, Inc. (VSTM)
Table 1. Insider trading of Fresh Tracks Therapeutics, Inc. (VICL) by Sherwin Stephen A
| Trade Date | Symbol | Trade Type | Shares | Price ($) | Value ($) |
|---|
| 2013-05-23 | VICL | Buy | 7,003 | .01 | 70 |
Table 2. Insider trading of Cell Genesys Inc (CEGE) by Sherwin Stephen A
| Trade Date | Symbol | Trade Type | Shares | Price ($) | Value ($) |
|---|
| 2005-06-08 | CEGE | Buy | 2,500 | 4.96 | 12,387 |
Table 3. Insider trading of Biogen Inc. (BIIB) by Sherwin Stephen A
| Trade Date | Symbol | Trade Type | Shares | Price ($) | Value ($) |
|---|
| 2025-03-07 | BIIB | Sale | 8,760 | 150.02 | 1,314,140 |
| 2020-03-11 | BIIB | Option Ex | 12,278 | 58.46 | 717,771 |
| 2020-03-11 | BIIB | Sale | 2,434 | 295.25 | 718,645 |
| 2015-03-10 | BIIB | Option Ex | 6,000 | 59.82 | 358,920 |
| 2015-03-10 | BIIB | Sale | 6,000 | 409.67 | 2,458,020 |
| 2014-01-02 | BIIB | Option Ex | 5,500 | 59.82 | 329,010 |
| 2014-01-02 | BIIB | Sale | 5,500 | 279.17 | 1,535,429 |
| 2013-06-03 | BIIB | Sale | 12,825 | 233.02 | 2,988,532 |
| 2013-06-03 | BIIB | Option Ex | 12,825 | 59.82 | 767,191 |
| 2013-03-22 | BIIB | Sale | 1,500 | 176.88 | 265,320 |
| 2012-09-04 | BIIB | Sale | 2,000 | 145.90 | 291,800 |
| 2012-06-04 | BIIB | Sale | 2,500 | 126.45 | 316,125 |
| 2011-12-19 | BIIB | Sale | 2,500 | 110.88 | 277,200 |
Table 4. Insider trading of Neurocrine Biosciences Inc (NBIX) by Sherwin Stephen A
| Trade Date | Symbol | Trade Type | Shares | Price ($) | Value ($) |
|---|
| 2025-05-22 | NBIX | Option Ex | 2,869 | .00 | 0 |
| 2025-02-13 | NBIX | Sale | 13,831 | 116.69 | 1,613,925 |
| 2024-05-29 | NBIX | Option Ex | 40,000 | 45.33 | 1,813,000 |
| 2024-05-29 | NBIX | Sale | 40,000 | 133.47 | 5,338,600 |
| 2024-05-17 | NBIX | Option Ex | 4,199 | .00 | 0 |
| 2023-01-03 | NBIX | Sale | 30,000 | 118.86 | 3,565,740 |
| 2023-01-03 | NBIX | Option Ex | 30,000 | 12.85 | 385,350 |
| 2023-01-03 | NBIX | Sale | 30,000 | 118.86 | 3,565,740 |
| 2023-01-03 | NBIX | Option Ex | 30,000 | 12.85 | 385,350 |
| 2022-01-24 | NBIX | Option Ex | 15,000 | 6.66 | 99,900 |
| 2022-01-24 | NBIX | Sale | 15,000 | 74.42 | 1,116,375 |
| 2020-04-28 | NBIX | Sale | 17,687 | 99.39 | 1,757,963 |
| 2018-06-11 | NBIX | Sale | 10,000 | 98.44 | 984,419 |
| 2018-04-26 | NBIX | Option Ex | 15,000 | 7.05 | 105,750 |
| 2017-02-07 | NBIX | Option Ex | 15,000 | 3.40 | 51,000 |
| 2016-04-14 | NBIX | Option Ex | 15,000 | 3.07 | 46,050 |
| 2015-04-07 | NBIX | Option Ex | 15,000 | 4.76 | 71,400 |
| 2014-04-16 | NBIX | Option Ex | 12,000 | 12.37 | 148,440 |
| 2013-03-28 | NBIX | Option Ex | 12,000 | 10.60 | 127,200 |
Table 5. Insider trading of Verastem, Inc. (VSTM) by Sherwin Stephen A
| Trade Date | Symbol | Trade Type | Shares | Price ($) | Value ($) |
|---|
| 2014-12-26 | VSTM | Buy | 2,500 | 8.56 | 21,395 |
Insider trading activities including stock purchases, stock sales, and option exercises
listed in the above table cannot be completely guaranteed as to their accuracy.
For more information regarding the trades made by Sherwin Stephen A
(Director of Neurocrine Biosciences Inc at the time of this reporting) see
the Securities and Exchange Commission (SEC) website.